Atlas Trials

The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs

Clinical trial NCT06325826 · UNKNOWN

Trial details

NCT number
NCT06325826
Sponsor
Egyptian Liver Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
Hepatocellular Carcinoma
Start date
2022-02-01
Primary completion
2023-06-30
Enrollment
500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.